A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib

J Invest Dermatol. 2014 May;134(5):1473-1476. doi: 10.1038/jid.2013.525. Epub 2013 Dec 6.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Benzamides / therapeutic use*
  • Cell Line, Tumor
  • Humans
  • Imatinib Mesylate
  • Melanoma / drug therapy*
  • Melanoma / genetics*
  • Melanoma / metabolism
  • Piperazines / therapeutic use*
  • Point Mutation
  • Proto-Oncogene Proteins c-kit / genetics*
  • Proto-Oncogene Proteins c-kit / metabolism
  • Pyrimidines / therapeutic use*
  • Signal Transduction / genetics
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / metabolism

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit